Sanofi Upbeat On Itepekimab, Rilzabrutinib And Oral IRAK4 Protein Degrader

15 Immunologics In Active Development

Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.  

Molecular model of an antibody
Antibodies Involved In Immune Responses • Source: Shutterstock

Sanofi's research executives highlighted the start of Phase III studies with the anti-IL-33 Mab itepekimab in chronic obstructive pulmonary disease (COPD), and the expansion of Phase II studies of the selective BTK inhibitor, rilzabrutinib, into atopic dermatitis, asthma and chronic spontaneous urticaria, during the company’s Capital Markets Day on 5 February. 

Three years on from the start of retargeting and reorganizing R&D at Sanofi on specialty rather than primary care, Sanofi’s R&D chief John Reed noted the changes had required “enormous trade-offs”, including exiting research areas like cardiovasculars and diabetes, and optimizing the number of research sites, but

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

More from Therapy Areas